Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 92,200 Shares

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 92,200 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of C$6.15, for a total transaction of C$567,030.00.

Sime Armoyan also recently made the following trade(s):

• On Thursday, March 13th, Sime Armoyan sold 1,100 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.10, for a total transaction of C$6,710.00.
• On Tuesday, March 4th, Sime Armoyan acquired 17,600 shares of Knight Therapeutics stock. The stock was purchased at an average price of C$5.48 per share, for a total transaction of C$96,488.48.

Knight Therapeutics Stock Up 0.2 %

Shares of GUD stock traded up C$0.01 during trading on Tuesday, hitting C$6.18. 70,965 shares of the company were exchanged, compared to its average volume of 68,064. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The firm has a market capitalization of C$625.11 million, a price-to-earnings ratio of -20.63, a P/E/G ratio of -1,013.50 and a beta of 0.50. The business’s 50-day simple moving average is C$5.61 and its 200 day simple moving average is C$5.56. Knight Therapeutics Inc. has a twelve month low of C$5.09 and a twelve month high of C$6.25.

Wall Street Analyst Weigh In

Separately, Research Capitl raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. Two investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Knight Therapeutics presently has an average rating of “Strong Buy” and a consensus target price of C$7.08.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.